Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43851   clinical trials with a EudraCT protocol, of which   7283   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-002260-14
    Sponsor's Protocol Code Number:UC-0105/1612
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2017-04-07
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2016-002260-14
    A.3Full title of the trial
    Secured access to pembrolizumab for adult patients with selected rare cancer types.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    _
    A.3.2Name or abbreviated title of the trial where available
    AcSé Pembrolizumab
    A.4.1Sponsor's protocol code numberUC-0105/1612
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorUNICANCER
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportLaboratoire M.S.D
    B.4.2CountryFrance
    B.4.1Name of organisation providing supportLA LIGUE
    B.4.2CountryFrance
    B.4.1Name of organisation providing supportInstitut National du Cancer
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationUNICANCER
    B.5.2Functional name of contact pointDaniel COUCH, Project Leader
    B.5.3 Address:
    B.5.3.1Street Address101, rue de Tolbiac
    B.5.3.2Town/ cityParis cedex 13
    B.5.3.3Post code75654
    B.5.3.4CountryFrance
    B.5.4Telephone number33180 50 12 96
    B.5.5Fax number33171 93 61 67
    B.5.6E-maild-couch@unicancer.fr
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePembrolizumab
    D.3.2Product code MK-3475
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPEMBROLIZUMAB
    D.3.9.1CAS number 1374853-91-
    D.3.9.4EV Substance CodeSUB167136
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Patients with unresectable locally advanced or metastatic, rare soft tissue sarcoma, visceral sarcoma, or bone sarcoma, rare ovarian cancer, primary central nervous system lymphomas (PCNSL), rare thyroid cancer, rare malignant neuroendocrine cancer or germ-cell cancer, which is resistant or refractory to standard therapy, or for which standard therapy does not exist, or is not considered appropriate, and for which no other experimental treatment options are available.
    E.1.1.1Medical condition in easily understood language
    Rare cancer resistant to standard therapy.
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of the trial is to evaluate the response to pembrolizumab monotherapy in cohorts of patients with unresectable locally advanced or metastatic, rare soft tissue sarcoma, visceral sarcoma, or bone sarcoma, rare ovarian cancer, PCNSL, rare thyroid cancer, rare malignant neuroendocrine cancer or germ-cell cancer, which is resistant or refractory to standard therapy, and for which no other treatment options are available.
    E.2.2Secondary objectives of the trial
    - To identify populations, for which the IP is expected to have a clinical benefit.
    - To assess the efficacy of pembrolizumab monotherapy in each cohort in terms of survival, progression occurrence and quality of response.
    - To assess the safety profile of pembrolizumab monotherapy.
    - To define predictive factors including biomarkers related to the response to pembrolizumab; in particular to explore whether the immunohistochemical expression of PD-L1 and other immune markers (CD3, CD4, FOXP3, CD8 or CD68/CD163) in the tumour samples (both in the tumour cells and the immune cells) is correlated with response to pembrolizumab.
    - To test if the mutational load measured in tumour samples from some of the studied cohorts can be correlated with response to pembrolizumab.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    - To identify the discriminant molecular mechanisms in patients with tumour response versus patients without tumour response within the same cohort.
    E.3Principal inclusion criteria
    Patients must meet all of the following criteria to be included in the study:
    1. Patient information sheet and written informed consent form signed.
    2. Histologically confirmed diagnosis of a pathology corresponding to one of the following selected cancer types:
    -Rare sarcoma: Alveolar soft part sarcoma, Chordoma, Dedifferentiated chondrosarcoma, epithelioid sarcoma, sarcoma with loss of INI1, malignant rhabdoid tumours, myxoid liposarcoma, angiosarcoma of the scalp, radiation induced sarcomas.
    -Rare ovarian cancer: recurrent or relapsed; sex cord tumour, germ cell tumour (immature teratoma, non seminomatous germ cell & dysgerminoma), low-grade serous carcinoma, mucinous carcinoma, clear cell adenocarcinoma, small cell carcinoma, and carcinosarcoma – with histological confirmation following review by members of the Tumeurs Malignes Rares Gynécologiques (TMRG) network (French rare gynaecological tumour group)
    -Primary central nervous system lymphoma: refractory primary intraocular and CNS lymphoma.
    -Rare thyroid cancer: differentiated thyroid carcinoma (Papillary, follicular, Hurthle cell (oncocytic), poorly differentiated thyroid carcinoma), medullary thyroid carcinoma, anaplastic thyroid carcinoma.
    -Rare malignant neuroendocrine cancer: poorly differentiated tumours refractory after 2 lines of chemotherapy, well differentiated tumours refractory after 4 lines of treatment, carcinoid tumours after 2 lines of treatment.
    -Germ-cell cancer progressing after standard therapy.
    3. Metastatic disease or unresectable locally advanced malignancy that is resistant or refractory to standard therapy or for which standard therapy does not exist or is not considered appropriate by the Investigator.
    4. Aged ≥ 18 years old.
    5. Measurable disease according to RECIST v1.1 guidelines for solid tumours (Eisenhauer, 2009); or IPCG response criteria (Abrey, 2005) for patients in the PCNSL cohort. For patients with germ-cell cancer measurable disease is defined as measurable according to RECIST v1.1 and / or abnormal levels of AFP, hCG and LDH.
    6. Able to provide a FFPE biopsy sample of a metastatic site or primitive tumour tissue.
    Note: Patients for whom suitable archived biopsy material is not available must be willing to undergo a biopsy of a tumour lesion prior to study entry, unless this is medically contraindicated (e.g. site inaccessible or patient safety concerns).
    7. Patients must have a mandatory treatment-free interval of at least 21 days following previous systemic anti-cancer treatments.
    8. Patients who have received previous systemic anticancer treatment and/or radiotherapy should have recovered from any treatment related toxicity, to a level of ≤ grade 1 (according to National Cancer Institute [NCI] common terminology criteria for adverse events, version 4 (CTCAE v4) with the exception of Grade 2 alopecia.
    9. Adequate hematologic function (absolute neutrophil count ≥ 1.0 x109/L, platelets ≥ 100 x109/L, haemoglobin ≥ 9 g/L) measured within 14 days of treatment initiation.
    10. Adequate renal function (creatinine clearance ≥ 50 mL/min using the MDRD or CKI EPI method) measured within 14 days of treatment initiation.
    11. Adequate hepatic function (serum bilirubin ≤ 1.5 xULN unless due to Gilbert’s syndrome; aspartate aminotransferase [ASAT] and alanine aminotransferase [ALAT] ≤ 3 xULN) measured within 14 days of treatment initiation. For patients with documented liver metastasis ASAT/ALAT ≤ 5x ULN is acceptable.
    12. Strictly normal blood levels of calcium and magnesium, measured within 14 days of treatment initiation.
    13. Eastern Cooperative Oncology Group Performance Status of ≤ 1.
    14. Estimated life expectancy ≥ 90 days.
    15. Patients who are sexually active must agree to use a medically accepted method of contraception (e.g. implants, injectables, combined oral contraceptives, some intrauterine devices or vasectomized partner, for participating women; condoms for participating men) or practice complete abstinence, beginning 14 days before the first administration of IP, while on treatment and for at least 5 months after the last administration of IP for female patients, and 7 months after the last administration of IP for male patients.
    16. Women of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to the first administration of IP. If urine test results are positive or cannot be confirmed as negative, a serum pregnancy test will be required.
    17. Women who are breastfeeding should discontinue nursing prior to the first administration of IP and for at least 90 days after the last administration of IP.
    18. Patients must be affiliated to a Social Security System or equivalent.
    E.4Principal exclusion criteria
    Patients meeting any of the following criteria will be excluded from participation in the study:
    1. Prior treatment with an anti-PD1 or anti-PD-L1 antibody.
    2. Eligible, and willing, to participate in a clinical trial of an alternative anticancer therapy targeting their disease, which is open to accrual in France.
    3. Concurrent steroid medication at a dose greater than prednisone 10 mg/day or equivalent. For patients with PCNSL or germ-cell cancer, concurrent steroid medication at a dose greater than prednisone 20 mg/day or equivalent.
    4. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
    5. History of (non-infectious) pneumonitis that required steroids, or current pneumonitis.
    6. History of severe hypersensitivity reaction to any monoclonal antibody therapy
    7. Radiotherapy (except for brain and extremities) within 21 days prior to the first administration of IP.
    8. Treatment with other investigational drugs or participation in another clinical trial within 21 days prior to the first administration of IP or concomitantly with the trial.
    9. Has known symptomatic central nervous system (CNS) metastases. Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment.
    10. Has known carcinomatous meningitis or a history of leptomeningeal disease except for patients with primary CNS lymphoma.
    11. Serum creatinine > 1.5 xULN or glomerular filtration rate < 50 ml/min.
    12. Lymphocytes count below 1,000/mm3 and CD4+ count below 500/mm3 as assessed by routine blood phenotyping.
    13. Other malignancies within the past 5 years other than basal cell skin cancer or in situ carcinoma of the cervix.
    14. Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy.
    15. Active or chronic hepatitis B, hepatitis C and/or human immunodeficiency virus infection (HIV 1/2 antibodies), or a known history of active Tuberculosis bacillus.
    16. Live vaccine received within 30 days of planned start of study treatment.
    Note: Seasonal influenza vaccines for injection are generally inactivated vaccines and are allowed; however intranasal influenza vaccines (e.g. Flu-Mist®) are live attenuated vaccines, and are not allowed.
    17. Active alcohol or drug abuse.
    18. Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule.
    19. Any condition which in the Investigator’s opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol.
    E.5 End points
    E.5.1Primary end point(s)
    Objective response rate (ORR) per cohort, defined as the percentage of patients in each cohort with a complete response (CR) or partial response (PR), measured at the first scheduled disease assessment following study treatment initiation (Day 84, ± 7 days) as assessed by an IRC according to RECIST v1.1 for patients with solid tumours, or RECIST v1.1 combined with biomarker assessment for patients with germ-cell cancer, or the IPCG response criteria for patients with PCNSL.
    Patients who withdraw from the study prior to this time point and patients with non-evaluable disease will be considered as ‘non-responders’.
    E.5.1.1Timepoint(s) of evaluation of this end point
    _
    E.5.2Secondary end point(s)
    - Progression-free survival, defined as the time from inclusion until documented disease progression (PD) according to RECIST v1.1, or RECIST v1.1 combined with biomarker assessment, or IPCG response criteria, or death, whichever occurs first.
    - Overall survival, defined as the time from inclusion until death due to any cause.
    - Best response to treatment according to RECIST v1.1, or RECIST v1.1 combined with biomarker assessment, or IPCG response criteria, measured at any disease assessment during the course of the study.
    - Response duration, defined as the time from first observation of objective response (i.e. PR or CR) according to RECIST v.1.1, or RECIST v1.1 combined with biomarker assessment, or IPCG response criteria, until PD or death, whichever occurs first.
    - Time to response, defined as the time from inclusion until observation of objective response (i.e. PR or CR) according to RECIST v1.1, or RECIST v1.1 combined with biomarker assessment, or IPCG response criteria, during the course of the study.
    - Frequency and severity of adverse events assessed according to the NCI CTCAE v4.
    - Progression-free survival, OS and ORR in subgroups of patients according to expression level of PD-L1 and other immune markers (high versus low expression with a cut-off value set at the median for the population measured).
    E.5.2.1Timepoint(s) of evaluation of this end point
    _
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned20
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years6
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 150
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 150
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state300
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-04-03
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-03-14
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2023-12-14
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 20 13:02:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA